Do you have any concerns wrt the partnership announcement today between GLPG and GILD for filgotinib? They are behind at least 2-3 years behind INCY but they said that: " In more than 700 patient years of rheumatoid arthritis (RA) clinical study experience, filgotinib has shown a rapid onset of action, potentially best-in-class efficacy and to be safe and well tolerated in these so called DARWIN studies".
I don't know how to justify this claim?
Please share your thoughts and insights. Thanks!